TY - JOUR
T1 - The start-ups taking nanoneedles into the clinic
AU - Elnathan, Roey
AU - Tay, Andy
AU - Voelcker, Nicolas H.
AU - Chiappini, Ciro
N1 - Funding Information:
Cytosurge sold its unique atomic force microscopy hollow probe right from the early stages. Behr says Cytosurge had a profitable margin from the start, allowing them to operate at a small scale for several years. Then Cytosurge accessed Swiss National Science Foundation funding, which enabled ETH Zürich and the company to share PhD students. This was important in developing FluidFM at reasonable cost. Cytosurge’s initial idea was to manufacture only hollow FluidFM nanoprobes, but at a certain stage they made the decision to design their own atomic force microscopy instruments, decoupling from external tool manufacture to exercise closer control over the process. Cytosurge technology was so versatile and disruptive that it gave birth to another spin-off, Exaddon, which now specializes in three-dimensional electrochemical metal microprinting.
Funding Information:
A.T. would like to acknowledge the support of the NUS Presidential Young Professorship, MOE Tier 1 grant and NMRC OF-YIRG.CC acknowledges funding from the European Research Council Starting Grant (ENBION 759577) and the Medical Research Council (MC_PC_16048). R.E. would like to acknowledge that this work was in part funded by the Australian Government (ARC DECRA project number: DE170100021); R.E., N.H.V. acknowledge the ARC Training Centre for Cell & Tissue Engineering Technologies (IC190100026).
PY - 2022/8
Y1 - 2022/8
N2 - Nanotechnology has matured to the point where it provides exquisite solutions to key challenges across medicine and biology, as seen in the success of delivery nanovectors for COVID-19vaccines1. Among these nanotechnologies, nanoneedles — vertical arrays of high aspect-ratio nanomaterials — have emerged as a simple, controllable and powerful tool to efficiently access cells with minimalperturbation2. Nanoneedles are rapidly emerging as competitive solutions forsensing3, and offer a path to transforming gene and cell therapies4,5. Realizing the transformative potential of nanoneedles is a work in progress. In this Comment, we discuss the burgeoning advances and strong commercial activities of nanoneedle technology through the eyes of leading researchers, entrepreneurs and venture capitalists — all of them major players in the evolution of a viable nanoneedle technology for sensing and clinical use.
AB - Nanotechnology has matured to the point where it provides exquisite solutions to key challenges across medicine and biology, as seen in the success of delivery nanovectors for COVID-19vaccines1. Among these nanotechnologies, nanoneedles — vertical arrays of high aspect-ratio nanomaterials — have emerged as a simple, controllable and powerful tool to efficiently access cells with minimalperturbation2. Nanoneedles are rapidly emerging as competitive solutions forsensing3, and offer a path to transforming gene and cell therapies4,5. Realizing the transformative potential of nanoneedles is a work in progress. In this Comment, we discuss the burgeoning advances and strong commercial activities of nanoneedle technology through the eyes of leading researchers, entrepreneurs and venture capitalists — all of them major players in the evolution of a viable nanoneedle technology for sensing and clinical use.
UR - http://www.scopus.com/inward/record.url?scp=85132898617&partnerID=8YFLogxK
U2 - 10.1038/s41565-022-01158-5
DO - 10.1038/s41565-022-01158-5
M3 - Comment / Debate
C2 - 35760894
AN - SCOPUS:85132898617
VL - 17
SP - 807
EP - 811
JO - Nature Nanotechnology
JF - Nature Nanotechnology
SN - 1748-3387
IS - 8
ER -